Jupiter Neurosciences

NASDAQ: JUNS ↗$0.14 USD~$50M (small-cap) MCAP

#CNS #Neurodegeneration #Psychedelic-Assisted Therapy

Jupiter Neurosciences is a clinical-stage pharmaceutical company developing treatments for central nervous system (CNS) disorders, with a focus on psychedelic-assisted therapy and neurodegenerative diseases. The company is advancing JNS-101 (MDMA analog) and other CNS-targeting candidates.

Company Info

Sector:Clinical-stage CNS pharmaceuticals

Headquarters:Miami, Florida, United States

Founded:2018

Website:jupiterneurosciences.com

Upcoming Milestones & Key Dates

Q3 2026

Regulatory

MDMA analog IND-enabling studies

Q4 2026

Clinical

First-in-human study design

Clinical Development Pipeline

JNS-101 (MDMA analog)

Target: MDMA receptor

PTSD and treatment-resistant depression

Preclinical

Phase 1

Phase 2

Phase 3

Approved

JNS-102

Target: Mitochondrial function

Parkinson's disease cognitive impairment

Preclinical

Phase 1

Phase 2

Phase 3

Approved

JNS-103

Target: Ion channel

Rare pediatric epilepsy

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Jupiter enters psychedelics space with $100M deal for MDMA drug ↗

Jupiter enters psychedelics space with $100M deal for MDMA drug.

Leadership Team

Chris Bringhurst

Chief Executive Officer

Dianne K. Bryant

Chief Medical Officer

Hollie S. Arnold

Chief Financial Officer

Careers & Job Openings

See all open roles

Apply Now →